Abstract:Background & Aims: Approximately 10 million people live with chronic HCV infection in China, and less than 20% of people with HCV were diagnosed. We aim to determine the cost-effectiveness of one-time HCV screening compared with no screening in the Chinese population from the healthcare system perspective. Methods: A decision -tree plus Markov model was adopted to project chronic hepatitis C (CHC) prevalence, probability of complications, quality -adjusted life years (QALYs), and costs in the Chinese general population undiagnosed for CHC for different screening strategies. Once CHC was diagnosed, pan -genotypic direct -acting antiviral agent treatment was administered regardless of fibrosis. The population was simulated in a model spanning a lifetime. Input parameters were obtained from published literature. The incremental cost-effectiveness ratio between screening and no screening was estimated. The one-time Chinese gross domestic product per capita in 2021 ($12,558/QALY) was used as the willingness -to -pay threshold. Results: Universal screening in the population aged 3-80 years led to the lowest probability of complications, which yielded a 62% reduction of excess mortality. Compared with no screening, implementing screening and treatment for HCV in populations aged 3-80 years resulted in the greatest marginal QALYs (15.2 per 1,000 population) with an increase in total costs of $109,136. Calculating the incremental cost-effectiveness ratio yields a value of $9,503/QALY (95% uncertainty interval $3,738- $22,566). The robustness of the model was demonstrated through various sensitivity analyses. If the CHC prevalence was over 0.3%, screening could be cost-effective. Conclusions: HCV screening for Chinese people aged 3-80 years may be a cost-effective intervention to reduce the disease burden related to HCV infection. This strategy should certainly be implemented. Impact and implications: This study found that screening Chinese people aged 3-80 years yielded the greatest health benefits and was a cost-effective alternative. The findings indicated that national efforts eliminating HCV should be invested and strengthened in China. The results of this study are important because they provide strong evidence that universal screening can be a cost-effective way to reduce the burden of HCV in China. These findings are important for policymakers, physicians, patients, caregivers, and the public because they promote awareness and inform decision -making for HCV prevention and treatment. (c) 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Dual strategy involving hospital-based study and community-based screening to eliminate hepatitis C in remote areas

Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study

Community-based screening by Anti-HCV reflex HCV Ag test and accessible post-screening care toward elimination of hepatitis C in two hyperendemic townships

Establishment and Development of National Community-Based Collaborative Innovation Demonstration Areas to Achieve the Control Target of Hepatitis B in China

Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community

Multi-disciplinary cooperation for the micro-elimination of hepatitis C in China: a hospital-based experience

Hepatitis C screening in hospitals: find the missing patients

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Universal Screening and Treatment Towards the Elimination of Chronic Hepatitis C in China: an Economic Evaluation

Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)

Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan

Universal Screening for HCV Infection in China: an Effectiveness and Cost-Effectiveness Analysis

A System Dynamics Modelling Simulation Based on a Cohort of Hepatitis B Epidemic Research in East China Community

Above-Standard Survival of Hepatocellular Carcinoma as the Final Outcome of Comprehensive Hepatology Care Programs in a Remote HCV-Endemic Area

Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan

Strategy for the Micro-Elimination of Hepatitis C among Patients with Diabetes Mellitus—A Hospital-Based Experience

Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study.

Prevalence and Influencing Factors of Hepatitis B among a Rural Residential Population in Zhejiang Province, China: a Cross-Sectional Study

Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: Promoting the early detection of hepatocellular carcinoma in China